On September 8, 2021 NETRIS Pharma reported that a "trial in progress" abstract has been accepted to the ESMO (Free ESMO Whitepaper) congress (European Society for Medical Oncology) taking place September 16th-20th (Press release, Netris Pharma, SEP 8, 2021, View Source [SID1234587455]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The corresponding e-Poster "GYNET – Safety & efficacy of NP137 in combination with chemotherapy and/or Pembrolizumab in patients with pretreated locally advanced/metastatic endometrial carcinoma or cervix carcinoma: an adaptative multi-arms randomized Phase I/II" will be presented by Prof. Isabelle Ray-Coquard as Principal Investigator.